Cargando…
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
Autores principales: | Dieci, Maria Vittoria, Carbognin, Luisa, Miglietta, Federica, Canino, Fabio, Giorgi, Carlo Alberto, Cumerlato, Enrico, Amato, Ottavia, Massa, Davide, Griguolo, Gaia, Genovesi, Elisa, Garufi, Giovanna, Giannarelli, Diana, Tornincasa, Antonio, Trudu, Lucia, Michieletto, Silvia, Saibene, Tania, Lo Mele, Marcello, Fassan, Matteo, Zarrilli, Giovanni, Piacentini, Federico, Bria, Emilio, Guarneri, Valentina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902395/ https://www.ncbi.nlm.nih.gov/pubmed/36460777 http://dx.doi.org/10.1038/s41416-022-02087-9 |
Ejemplares similares
-
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022) -
Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2020) -
The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies
por: Zarrilli, Giovanni, et al.
Publicado: (2020) -
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
por: Miglietta, Federica, et al.
Publicado: (2019) -
Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)